IDSC 2025丨Professor Yoshiaki Gu: From National Action to One Health Strategy – Japan’s Experience and Future Pathways in AMR Control

IDSC 2025丨Professor Yoshiaki Gu: From National Action to One Health Strategy – Japan’s Experience and Future Pathways in AMR Control

2025.08.08
ntimicrobial resistance (AMR) has become a major global public health challenge. To enhance capabilities in diagnosing and treating infectious diseases and promote rational use of antimicrobial agents in China, the 11th Academic Conference of the Infectious Diseases Society of China (IDSC) under the China Medicine Education Association was recently held in Beijing. At the conference, Professor Yoshiaki Gu from the Institute of Science Tokyo (Science Tokyo) shared Japan’s experience in AMR control. Infectious Disease Frontier invited Professor Gu to provide an in-depth analysis of the evolving threat of drug-resistant pathogens in Japan, the outcomes of its National Action Plan, and innovative public education initiatives. He further explored critical future directions for antimicrobial drug development and cross-sectoral collaboration under the "One Health" strategy.
Professor Dingwei Ye’s Team Showcases Surgical Expertise in Recurrent Prostate Cancer at the World Robotic Surgery Congress

Professor Dingwei Ye’s Team Showcases Surgical Expertise in Recurrent Prostate Cancer at the World Robotic Surgery Congress

2025.08.07
From July 15 to 18, 2025, the annual global summit in the field of robotic surgery—the World Congress of the Society of Robotic Surgery (SRS)—was held in France, drawing together leading surgeons and pioneers in robotic technology from around the world. The event featured discussions on cutting-edge innovations and future trends, along with the presentation of dozens of state-of-the-art surgical robot platforms and their development teams. Representing one of China’s foremost urologic oncology institutions, the Department of Urology at Fudan University Shanghai Cancer Center, led by Professor Dingwei Ye, actively participated in this global exchange, showcasing China’s expertise and innovation on the international stage.
Vitamin C Shows Promise in Treating Advanced Kidney Cancer: Breakthrough Mechanism Identified by Research Teams Led by Professors Liqun Zhou, Xuesong Li, and Weimin Ci

Vitamin C Shows Promise in Treating Advanced Kidney Cancer: Breakthrough Mechanism Identified by Research Teams Led by Professors Liqun Zhou, Xuesong Li, and Weimin Ci

2025.08.07
Vitamin C, a vital nutrient known for its antioxidant, immune-boosting, and cosmetic benefits, has long been a subject of interest in cancer research. While its anti-tumor properties have been explored for years, the scientific community has remained divided, and the precise mechanisms by which Vitamin C may act against cancer—particularly metastatic renal cell carcinoma (RCC)—have remained elusive.
2025 Beijing Breast Cancer Forum | Prof. Que Zhang: Enhancing Early Screening in Primary Care, Upholding the Mission of Breast Oncology Advancement

2025 Beijing Breast Cancer Forum | Prof. Que Zhang: Enhancing Early Screening in Primary Care, Upholding the Mission of Breast Oncology Advancement

2025.08.05
The 2025 Beijing Breast Cancer Forum and Breast Reconstruction Symposium, held from June 25 to June 28 in Beijing, was hosted by the Beijing Society for Breast Disease Prevention and Treatment and co-organized by the Breast Center of Peking University People’s Hospital and the Jiaqing Breast Cancer Prevention Foundation. During the conference, Oncology Frontier invited Prof. Que Zhang, Vice President of the Beijing Society for Breast Disease Prevention and Treatment, to provide in-depth insights into the current challenges and future directions of early breast cancer screening in primary care institutions in China. He also reflected on the broader significance of the newly launched “Peking University People’s Hospital Jiaqing Foundation Centennial Legacy Training Program.”
ASCO Highlights | Prof. Wenjin Yin: Who Benefits Most After CDK4/6i Failure? New Biomarker Insights from DESTINY-Breast06 Provide Clearer Answers

ASCO Highlights | Prof. Wenjin Yin: Who Benefits Most After CDK4/6i Failure? New Biomarker Insights from DESTINY-Breast06 Provide Clearer Answers

2025.08.05
There is currently no universally accepted standard treatment for patients who progress after receiving CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i + ET). In the era of precision medicine, both domestic and international guidelines increasingly recommend biomarker-driven treatment strategies. However, the population covered by each biomarker is often limited, creating an urgent clinical need for more potent and broadly applicable therapies that can simplify both diagnostic testing and treatment selection.
YBCSG 2025 Mid-Year Meeting | Prof. Hengyu Li: Advancing Liver Metastasis Management and Multidisciplinary Collaboration to Bring Hope to Breast Cancer Patients

YBCSG 2025 Mid-Year Meeting | Prof. Hengyu Li: Advancing Liver Metastasis Management and Multidisciplinary Collaboration to Bring Hope to Breast Cancer Patients

2025.08.04
The “YBCSG 2025 Mid-Year Breast Cancer Collaboration Meeting and Post-ASCO Symposium,” held recently in Shanghai, gathered experts to discuss clinical updates in breast cancer treatment. At the event, Prof. Hengyu Li—Secretary General of the Yangtze River Breast Cancer Study Group (YBCSG) and a leading expert at Shanghai Changhai Hospital, Naval Medical University—delivered a comprehensive presentation titled “Treatment Challenges of Breast Cancer Liver Metastases in 2025.” In an exclusive interview with Oncology Frontier, Prof. Li elaborated on YBCSG’s major achievements in the first half of 2025 and highlighted key challenges in managing liver metastases in breast cancer.
YBCSG 2025 Mid-Year Meeting | Prof. Leiping Wang: Latest Advances in HER2-Positive Breast Cancer at ASCO 2025 and Reflections on Clinical Practice

YBCSG 2025 Mid-Year Meeting | Prof. Leiping Wang: Latest Advances in HER2-Positive Breast Cancer at ASCO 2025 and Reflections on Clinical Practice

2025.08.04
At the recent "Yangtze Breast Cancer Collaboration Mid-Year Meeting and the Mid-Year Meeting of the Oncology Drug Clinical Research Committee of the Chinese Medical Education Association," Professor Leiping Wang from Fudan University Shanghai Cancer Center delivered a keynote presentation titled “New Advances in HER2-Positive Breast Cancer at ASCO 2025 and My Clinical Practice.” Oncology Frontier invited Prof. Wang for an exclusive interview to share insights on the key findings presented at the ASCO 2025 conference in the field of HER2-positive breast cancer and their clinical implications, along with perspectives on future research directions.